Xtandi
Sir Michael Parkinson criticises NICE
February 4, 2014Medical Communications, Sales and Marketing Astellas, NHS, NICE, Xtandi, parkinson, prostate
TV host Sir Michael Parkinson has told NICE that it must lift the restrictions imposed on Astellas’ new prostate cancer …
NICE looks at Xtandi again
January 28, 2014Sales and Marketing Astellas, NHS, NICE, Xtandi
NICE has announced it is to consult again on its decision to recommend Astellas Pharma’s prostate cancer drug Xtandi after …
Astellas seeks Xtandi extension
December 5, 2013Sales and Marketing Astellas, Cancer, EU, FDA, US, Xtandi
Astellas Pharma and development partner Medivation are seeking to extend the reach of oncology brand Xtandi by conducting a trial …
Bayer cancer drug gets EU approval
November 18, 2013Sales and Marketing Bayer, CHMP, EU, Xtandi, Zytiga, xofigo
Bayer’s prostate cancer treatment Xofigo has been shown the green light by the European Commission. Xofigo (radium Ra 223 dichloride) …
Astellas gets NICE nod
October 18, 2013Sales and Marketing Cancer, NHS, NICE, Xtandi
Astellas Pharma’s new prostate cancer drug Xtandi which has been shown to shrink and kill cancer cells, has been recommended …
Xtandi gets EU approval
June 26, 2013Sales and Marketing Astellas, FDA, Xtandi
Astellas Pharma’s Xtandi has been approved in the European Union for the treatment of adult men with advanced prostate cancer, …
Prostate cancer drug Xtandi gets nod
April 26, 2013Sales and Marketing Xtandi, Zytiga, prostate cancer
Astellas and Medivation have received a positive opinion from Europe’s Committee for Medicinal Products for Human Use (CHMP) for Xtandi, …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
